EFFICACY AND SAFETY OF GUSELKUMAB MAINTENANCE THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE: WEEK 48 ANALYSES FROM THE PHASE 2 GALAXI 1 STUDY

被引：0
|
作者：
Panaccione, Remo
Rubin, David T.
Sands, Bruce E.
Reinisch, Walter
D'Haens, Geert
Panes, Julian
Gonzalez, Susana
Weisel, Kathleen
Sahoo, Aparna
Frustaci, Mary Ellen S.
Yang, Zijiang
Sandborn, William J.
Afzali, Anita
Hisamatsu, Tadakazu
Danese, Silvio
Andrews, Jane M.
Feagan, Brian G.
机构：
来源：
GASTROENTEROLOGY | 2022年 / 162卷 / 07期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
888
引用
收藏
页码：S216 / S217
页数：2
相关论文
共 50 条
  • [31] Guselkumab efficacy and safety in East Asian participants with moderate to severely active Crohn's disease: Subgroup analysis of the GALAXI 2 & 3 Phase 3 studies
    Nakase, H.
    Chen, B.
    Cao, Q.
    Matsuoka, K.
    Hisamatsu, T.
    Park, D., I
    Wahking, B.
    Yiu, W. C.
    Zhuo, J.
    Chen, M.
    JOURNAL OF CROHNS & COLITIS, 2025, 19 : I1612 - I1613
  • [32] EFFICACY, SAFETY, TOLERABILITY OF USTEKINUMAB IN PEDIATRIC PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE: RESULTS FROM UNISTAR, A PHASE 1 STUDY
    Rosh, Joel R.
    Turner, Dan
    Griffiths, Anne M.
    Jacobstein, Douglas
    Adedokun, Omoniyi J.
    Padgett, Lakshmi
    Terry, Natalie A.
    O'Brien, Christopher D.
    Hyams, Jeffrey S.
    GASTROENTEROLOGY, 2020, 158 (06) : S235 - S236
  • [33] Efficacy, safety, and tolerability of ustekinumab in paediatric patients with moderately to severely active Crohn's disease: Results from, UniStar, a phase 1 study
    Rosh, J.
    Turner, D.
    Griffiths, A.
    Jacobstein, D.
    Adedokun, O.
    Padgett, L.
    Terry, N.
    O'Brien, C.
    Hyams, J.
    JOURNAL OF CROHNS & COLITIS, 2020, 14 : S107 - S109
  • [34] Ustekinumab in Paediatric Patients with Moderately to Severely Active Crohn's Disease: Pharmacokinetics, Safety, and Efficacy Results from UniStar, a Phase 1 Study
    Rosh, Joel R.
    Turner, Dan
    Griffiths, Anne
    Cohen, Stanley A.
    Jacobstein, Douglas
    Adedokun, Omoniyi J.
    Padgett, Lakshmi
    Terry, Natalie A.
    O'Brien, Christopher
    Hyams, Jeffrey S.
    JOURNAL OF CROHNS & COLITIS, 2021, 15 (11): : 1931 - 1942
  • [35] THE EFFICACY AND SAFETY OF GUSELKUMAB INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: PHASE 213 QUASAR STUDY RESULTS THROUGH WEEK 12
    Allegretti, Jessica R.
    Rubin, David T.
    Bressler, Brian
    Huang, Kuan-Hsiang G.
    Shipitofsky, Nicole
    Germinaro, Matthew
    Zhang, Hongyan
    Johanns, Jewel
    Feagan, Brian
    Sandborn, William J.
    Sands, Bruce E.
    Hisamatsu, Tadakazu
    Lichi, Gary R.
    Lichtenstein, Gary R.
    Panes, Julian
    Dignass, Axel
    GASTROENTEROLOGY, 2022, 162 (07) : S963 - S964
  • [36] Efficacy and safety of subcutaneous guselkumab in East Asian participants with moderately to severely active Crohn's disease: Subgroup analysis of the Phase 3 GRAVITI study
    Liu, W.
    Guo, H.
    Kim, T. O.
    Takeuchi, K.
    Hisamatsu, T.
    Fable, J.
    Olurinde, M.
    Wahking, B.
    Zhuo, J.
    Cao, Q.
    JOURNAL OF CROHNS & COLITIS, 2025, 19 : I1899 - I1901
  • [37] The efficacy and safety of guselkumab induction therapy in patients with moderately to severely active Ulcerative Colitis: Phase 2b QUASAR Study results through week 12
    Dignass, A.
    Rubin, D.
    Bressler, B.
    Huang, K. H.
    Shipitofsky, N.
    Germinaro, M.
    Zhang, H.
    Johanns, J.
    Feagan, B.
    Sandborn, W.
    Sands, B.
    Hisamatsu, T.
    Lichtenstein, G.
    Panes, J.
    Allegretti, J.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I025 - I026
  • [38] Guselkumab for the Treatment of Crohn's Disease: Induction Results From the Phase 2 GALAXI-1 Study
    Sandborn, William J.
    D'Haens, Geert R.
    Reinisch, Walter
    Panes, Julian
    Chan, Daphne
    Gonzalez, Susana
    Weisel, Kathleen
    Germinaro, Matthew
    Frustaci, Mary Ellen
    Yang, Zijiang
    Adedokun, Omoniyi J.
    Han, Chenglong
    Panaccione, Remo
    Hisamatsu, Tadakazu
    Danese, Silvio
    Rubin, David T.
    Sands, Bruce E.
    Afzali, Anita
    Andrews, Jane M.
    Feagan, Brian G.
    GASTROENTEROLOGY, 2022, 162 (06) : 1650 - +
  • [39] Efficacy and safety of vedolizumab SC in patients with moderately to severely active Crohn's disease: Results of the VISIBLE 2 study
    Vermeire, S.
    Sandborn, W.
    Baert, F.
    Danese, S.
    Kobayashi, T.
    Loftus, E. V., Jr.
    Bhatia, S.
    Kisfalvi, K.
    Rosario, M.
    Zhang, W.
    D'Haens, G.
    JOURNAL OF CROHNS & COLITIS, 2020, 14 : S020 - S021
  • [40] Efficacy of risankizumab rescue therapy in patients with moderately to severely active Crohn's Disease and inadequate response to risankizumab maintenance therapy
    Baert, F. J.
    Atreya, R.
    Kakuta, Y.
    Long, M.
    Roblin, X.
    Neimark, E.
    Song, A.
    Wallace, K.
    Kingys, K.
    Mallick, M.
    Liao, X.
    Lim, A.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I128 - I128
12345